Uncover key drivers, emerging technologies, and competitive movements shaping the radiopharmaceutical theranostics market from 2026–2035 with trusted insights from The Business Research Company
Across 2026–2030, what is the expected market valuation path of the Radiopharmaceutical Theranostics Market?
The radiopharmaceutical theranostics market has experienced swift expansion in recent years. This market is projected to expand from $3.27 billion in 2025 to $3.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.0%. The growth observed in the past can be ascribed to several factors, including the expansion of nuclear medicine applications, increasing cancer incidence rates, advancements in radioisotope production techniques, growth in diagnostic imaging integration, and the early adoption of theranostic treatment models.
The radiopharmaceutical theranostics market is anticipated to experience swift expansion over the coming years, projected to reach $6.64 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.3%. This projected growth during the forecast period is fueled by several factors, including increasing investments within precision oncology, a heightened demand for customized radiopharmaceutical therapies, the broadening of clinical trials involving new isotopes, greater cooperation between diagnostic and therapeutic sectors, and continuous advancements in isotope supply chains. Key trends identified for this period encompass the escalating development of targeted theranostic radiopharmaceuticals, an increase in the application of PET-based personalized treatments, the expanding acceptance of alpha and beta emitters within oncology, the growth in cyclotron-based isotope manufacturing, and a sharpened emphasis on precision oncology applications.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11951&type=smp
Which Drivers Are Supporting The Rise Of The Radiopharmaceutical Theranostics Market?
The expanding occurrence of cancer is projected to boost the radiopharmaceutical theranostics market in the future. Cancer is characterized as a health condition involving the intricate and irregular multiplication of cells that possess the ability to invade and disseminate to other bodily regions. Radiopharmaceutical theranostics supports cancer management through focused and individualized methodologies. As an illustration, the American Cancer Society, a US-based voluntary cancer health organization, reported that in 2023, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the US, potentially leading to around 609,820 cancer-related deaths. Moreover, it is projected that 88% of those diagnosed will be from the 50 years or above age group. Consequently, the increasing prevalence of cancer is fueling the expansion of the radiopharmaceutical theranostics market.
What Segments Are Identified Within The Structure Of The Radiopharmaceutical Theranostics Market?
The radiopharmaceutical theranostics market covered in this report is segmented –
1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers
2) By Source: Nuclear Reactors, Cyclotrons
3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes
4) By Indication: Oncology, Cardiology, Neurology, Other Indications
5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Alpha Emitters: Actinium-225, Radium-223, Bismuth-213, Other Alpha-Emitting Radiopharmaceuticals
2) By Beta Emitters: Iodine-131, Lutetium-177, Yttrium-90, Other Beta-Emitting Radiopharmaceuticals
3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG), Gallium-68, Carbon-11, Other PET Tracers
How Are Emerging Trends Affecting The Progression Of The Radiopharmaceutical Theranostics Market?
Leading companies within the radiopharmaceutical theranostics market are directing their efforts towards advancing theranostics designed for cancer treatment. Theranostic strategies are currently being examined for addressing rare diseases, aiming to offer targeted therapies and diagnostic insights for individuals with limited therapeutic choices, such as cancer. For example, in November 2023, GE HealthCare Technologies Inc., a medical technology firm situated in the US, unveiled theranostics solutions tailored for cancer. Theranostics represents an innovative domain of precision medicine that employs therapeutic agents alongside imaging technology to pinpoint and target cancer cells for elimination.
Which Leading Companies Dominate The Radiopharmaceutical Theranostics Market Share?
Major companies operating in the radiopharmaceutical theranostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.
Access The Complete Report For Deeper Market Insights:
How Does The Radiopharmaceutical Theranostics Market Perform Across Major Global Regions?
North America was the largest region in the radiopharmaceutical theranostics market in 2025. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Radiopharmaceutical Theranostics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=11951&type=smp
Browse Through More Reports Similar to the Global Radiopharmaceutical Theranostics Market 2026, By The Business Research Company
Radiotheranostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report
Theranostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report
Nuclear Medicine Radioisotopes Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model